BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $GILD readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04639986-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~Sacituzumab Govitecan-hziy readout (P3) · Gilead Sciences $GILD
DESCRIPTION:Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Me
 tastatic Breast Cancer (MBC)\n\nPrimary completion date: 2026-12 (estimate
 d) — month only\, shown on the 1st\nOriginally planned: 2022-12-14 (+47.
 6 months)\nPhase 3 · Oncology · Metastatic Breast Cancer\nEnrollment: 33
 1 · Sites: 43\n\nPrimary completion = last participant's primary-endpoint
  data collected\; topline results usually follow weeks to months later. Sp
 onsor-reported\, often an estimate. Not investment advice.\n\nhttps://data
 cutoff.com/radar.html?nct=NCT04639986\nhttps://clinicaltrials.gov/study/NC
 T04639986
URL:https://datacutoff.com/radar.html?nct=NCT04639986
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05396885-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~iMMagine-1 readout (P2) · Kite\, A Gilead Company $GILD
DESCRIPTION:Study of Anitocabtagene-autoleucel in Relapsed or Refractory Mu
 ltiple Myeloma (iMMagine-1)\n\nPrimary completion date: 2026-12 (estimated
 ) — month only\, shown on the 1st\nOriginally planned: 2024-05-31 (+30.0
  months)\nPhase 2 · Oncology · Multiple Myeloma\nEnrollment: 136 · Site
 s: 18\n\nPrimary completion = last participant's primary-endpoint data col
 lected\; topline results usually follow weeks to months later. Sponsor-rep
 orted\, often an estimate. Not investment advice.\n\nhttps://datacutoff.co
 m/radar.html?nct=NCT05396885\nhttps://clinicaltrials.gov/study/NCT05396885
URL:https://datacutoff.com/radar.html?nct=NCT05396885
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06029972-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:~PALEKONA readout (P2) · Gilead Sciences $GILD
DESCRIPTION:Study of Tilpisertib Fosmecarbil in Participants With Moderatel
 y to Severely Active Ulcerative Colitis\n\nPrimary completion date: 2027-0
 1 (estimated) — month only\, shown on the 1st\nOriginally planned: 2025-
 06 (+19.0 months)\nPhase 2 · GI·Renal·Heme · Ulcerative Colitis\nEnrol
 lment: 176 · Sites: 102\n\nPrimary completion = last participant's primar
 y-endpoint data collected\; topline results usually follow weeks to months
  later. Sponsor-reported\, often an estimate. Not investment advice.\n\nht
 tps://datacutoff.com/radar.html?nct=NCT06029972\nhttps://clinicaltrials.go
 v/study/NCT06029972
URL:https://datacutoff.com/radar.html?nct=NCT06029972
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382286-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:~ASCENT-04 readout (P3) · Gilead Sciences $GILD
DESCRIPTION:Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Tr
 eatment of Physician's Choice and Pembrolizumab in Patients With Previousl
 y Untreated\, Locally Advanced Inoperable o…\n\nPrimary completion date:
  2027-02 (estimated) — month only\, shown on the 1st\nPhase 3 · Oncolog
 y · Triple Negative Breast Cancer\, PD-L1 Positive\nEnrollment: 443 · Si
 tes: 504\n\nPrimary completion = last participant's primary-endpoint data 
 collected\; topline results usually follow weeks to months later. Sponsor-
 reported\, often an estimate. Not investment advice.\n\nhttps://datacutoff
 .com/radar.html?nct=NCT05382286\nhttps://clinicaltrials.gov/study/NCT05382
 286
URL:https://datacutoff.com/radar.html?nct=NCT05382286
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05186974-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~EVOKE-02 readout (P2) · Gilead Sciences $GILD
DESCRIPTION:Study of Sacituzumab Govitecan Combinations in First-line Treat
 ment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cance
 r (NSCLC)\n\nPrimary completion date: 2027-03 (estimated) — month only\,
  shown on the 1st\nOriginally planned: 2023-05 (+46.0 months)\nPhase 2 · 
 Oncology · Non-small Cell Lung Cancer\nEnrollment: 193 · Sites: 101\n\nP
 rimary completion = last participant's primary-endpoint data collected\; t
 opline results usually follow weeks to months later. Sponsor-reported\, of
 ten an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.ht
 ml?nct=NCT05186974\nhttps://clinicaltrials.gov/study/NCT05186974
URL:https://datacutoff.com/radar.html?nct=NCT05186974
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06727565-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~VELOCITY-HNSCC readout (P2) · Gilead Sciences $GILD
DESCRIPTION:Study of Novel Treatment Combination Therapies in Participants 
 With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression 
 Status\; Substudy-01\n\nPrimary completion date: 2027-03 (estimated) — m
 onth only\, shown on the 1st\nOriginally planned: 2026-08 (+7.0 months)\nP
 hase 2 · Oncology · Head and Neck Squamous Cell Carcinoma\nEnrollment: 3
 9 · Sites: 23\n\nPrimary completion = last participant's primary-endpoint
  data collected\; topline results usually follow weeks to months later. Sp
 onsor-reported\, often an estimate. Not investment advice.\n\nhttps://data
 cutoff.com/radar.html?nct=NCT06727565\nhttps://clinicaltrials.gov/study/NC
 T06727565
URL:https://datacutoff.com/radar.html?nct=NCT06727565
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06749054-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~Oral Lenacapavir readout (P2) · Gilead Sciences $GILD
DESCRIPTION:Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-
 1 in Treatment-experienced Adolescents and Children\n\nPrimary completion 
 date: 2027-03 (estimated) — month only\, shown on the 1st\nOriginally pl
 anned: 2026-03 (+12.0 months)\nPhase 2 · Infectious · HIV-1-infection\nE
 nrollment: 12 · Sites: 9\n\nPrimary completion = last participant's prima
 ry-endpoint data collected\; topline results usually follow weeks to month
 s later. Sponsor-reported\, often an estimate. Not investment advice.\n\nh
 ttps://datacutoff.com/radar.html?nct=NCT06749054\nhttps://clinicaltrials.g
 ov/study/NCT06749054
URL:https://datacutoff.com/radar.html?nct=NCT06749054
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633654-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~Sacituzumab govitecan-hziy (SG) readout (P3) · Gilead Sciences $G
 ILD
DESCRIPTION:Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Tr
 eatment of Physician's Choice in Patients With Triple Negative Breast Canc
 er Who Have Residual Invasive Disease Afte…\n\nPrimary completion date: 
 2027-06 (estimated) — month only\, shown on the 1st\nPhase 3 · Oncology
  · Triple Negative Breast Cancer\nEnrollment: 1514 · Sites: 378\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?n
 ct=NCT05633654\nhttps://clinicaltrials.gov/study/NCT05633654
URL:https://datacutoff.com/radar.html?nct=NCT05633654
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06253663-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~JKART-1 readout (P2) · Kite\, A Gilead Company $GILD
DESCRIPTION:Study of KTE-X19 in Adult Japanese Participants With Relapsed/R
 efractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Ly
 mphoblastic Leukemia\n\nPrimary completion date: 2027-07 (estimated) — m
 onth only\, shown on the 1st\nOriginally planned: 2027-05 (+2.0 months)\nP
 hase 2 · Oncology · Relapsed/Refractory Mantle Cell Lymphoma\, Relapsed/
 Refractory B-precursor Acute Lymphoblastic Leukemia\nEnrollment: 25 · Sit
 es: 9\n\nPrimary completion = last participant's primary-endpoint data col
 lected\; topline results usually follow weeks to months later. Sponsor-rep
 orted\, often an estimate. Not investment advice.\n\nhttps://datacutoff.co
 m/radar.html?nct=NCT06253663\nhttps://clinicaltrials.gov/study/NCT06253663
URL:https://datacutoff.com/radar.html?nct=NCT06253663
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645287-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~GS-3242 Tablet readout (P2) · Gilead Sciences $GILD
DESCRIPTION:A Study of GS-3242 in Combination With Lenacapavir Versus Bikta
 rvy in Virologically Suppressed People With HIV-1\n\nPrimary completion da
 te: 2027-08 (estimated) — month only\, shown on the 1st\nPhase 2 · Infe
 ctious · HIV-1-infection\nEnrollment: 175 · Sites: 59\n\nPrimary complet
 ion = last participant's primary-endpoint data collected\; topline results
  usually follow weeks to months later. Sponsor-reported\, often an estimat
 e. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0764
 5287\nhttps://clinicaltrials.gov/study/NCT07645287
URL:https://datacutoff.com/radar.html?nct=NCT07645287
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841990-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~B/F/TAF readout (P2) · Gilead Sciences $GILD
DESCRIPTION:Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by M
 outh in People With HIV-1 With Undetectable Virus Levels\n\nPrimary comple
 tion date: 2027-08 (estimated) — month only\, shown on the 1st\nPhase 2 
 · Infectious · HIV-1 Infection\nEnrollment: 125 · Sites: 2\n\nPrimary c
 ompletion = last participant's primary-endpoint data collected\; topline r
 esults usually follow weeks to months later. Sponsor-reported\, often an e
 stimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=N
 CT07841990\nhttps://clinicaltrials.gov/study/NCT07841990
URL:https://datacutoff.com/radar.html?nct=NCT07841990
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07912996-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~GS-1179 readout (P2) · Gilead Sciences $GILD
DESCRIPTION:Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seroposit
 ive Participants With Recurrent Genital Herpes\n\nPrimary completion date:
  2027-11 (estimated) — month only\, shown on the 1st\nPhase 2 · Infecti
 ous · HSV-2 Infection\nEnrollment: 300 · Sites: 0\n\nPrimary completion 
 = last participant's primary-endpoint data collected\; topline results usu
 ally follow weeks to months later. Sponsor-reported\, often an estimate. N
 ot investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07912996
 \nhttps://clinicaltrials.gov/study/NCT07912996
URL:https://datacutoff.com/radar.html?nct=NCT07912996
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
